HAV IgM ELISA Kit

Produktnummer ABIN997031

Dieses Colorimetric ELISA kit dient der quantitativen Messung von Hepatitis A Virus (HAV) HAV IgM.

Kurzübersicht für HAV IgM ELISA Kit (ABIN997031)

Target: HAV IgM (Anti-Hepatitis A Virus Antibody IgM (HAV IgM))

Reaktivität: Hepatitis A Virus (HAV)

Nachweismethode: Colorimetric

Methodentyp: Competition ELISA

Applikation: ELISA

Proben: Serum

Produktdetails HAV IgM ELISA Kit

Verwendungszweck: The HAV IgM ELISA test is an enzyme-linked immunosorbent assay (ELISA) which is used for the qualitative determination of IgM-class antibodies to hepatitis A virus in human serum/plasma.

Analytische Methode: Qualitative

Spezifität: 100%

Sensitivität: 100%

Anwendungsinformationen

Probenmenge: 100 μL

Testdauer: 1 - 2 h

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Haltbarkeit: 12-18 months

Details zu HAV IgM

Target: HAV IgM (Anti-Hepatitis A Virus Antibody IgM (HAV IgM))

Andere Bezeichnung: HAV IgM

Substanzklasse: Antibody

Hintergrund: Hepatitis A is a self-limited disease and chronic stage or other complications are rare. Infections occur early in life in areas where sanitation is poor and living conditions are crowded. With improved sanitation and hygiene, infections are delayed and consequently the number of persons susceptible to the disease increases. Because the disease is transmitted through the fecal-oral route in dense populated regions, an outbreak can arise from single contaminated source. The cause of hepatitis A is hepatitis A virus (HAV)-non enveloped positive strand RNA virus with a linear single strand genome, encoding for only one known serotype.

HAV has four major, structural polypeptides and it localizes exclusively in the cytoplasm of human hepatocytes. The infection with HAV induces strong immunological response and elevated levels first of IgM and then IgG are detectable within a few days after the onset of the symptoms. The presence of anti–HAV IgM is an important serological marker for early detection and observation of the clinical manifestation of the disease. Increasing levels of anti-HAV IgM are detectable about three weeks after exposure with highest titter after four to six weeks later. Within six months after infection IgM concentration declines to non-detectable levels.